Treatment-Related Adverse Events of Antibody Drug Conjugates Identified
Overall incidence of treatment-related adverse events was 91.2 percent and included lymphopenia, nausea, neutropenia
Overall incidence of treatment-related adverse events was 91.2 percent and included lymphopenia, nausea, neutropenia
Patients taking tradipitant demonstrated significant improvements in nausea compared with placebo.
Aponvie is a proprietary IV injectable emulsion formulation designed to directly deliver aprepitant as a 30-second IV injection.
HTX-019 is a proprietary IV injectable emulsion formulation designed to directly deliver aprepitant, a substance P/NK1 receptor antagonist, as a 30-second IV injection.
Intraoperative administration of dexamethasone linked to reduced 90-day mortality after surgery to remove solid tumors
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
Barhemsys is a selective dopamine-2 and dopamine-3 receptor antagonist.
Akynzeo is a combination of palonosetron, a 5-HT3 receptor antagonist, and fosnetupitant, a substance P/NK1 receptor antagonist.
The FDA has approved a new ready-to-dilute liquid formulation of Akynzeo® injection (fosnetupitant/palonosetron; Helsinn) for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, in combination with dexamethasone in adults.